Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 15/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.56 |
| ▸ | AR | P10275 | 3/20 | 0.56 |
| ▸ | CNR1 | P21554 | 4/20 | 0.50 |
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9355694 | 0.80 | ESR1 (0.67) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL29492899 | 0.80 | ESR1 (0.70) | ESR1ESR2ARTP53TDP1 | |
| SCHEMBL2614950 | 0.80 | ESR1 (0.70) | ESR1ESR2ARTP53TDP1 | |
| SCHEMBL8654061 | 0.79 | CNR2 (0.68) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL8061134 | 0.79 | CNR2 (0.68) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL6826195 | 0.79 | ESR1 (0.52) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL9355691 | 0.78 | ESR1 (0.61) | ESR1ESR2ARTP53TDP1 | |
| SCHEMBL17480253 | 0.78 | ESR1 (0.55) | ESR1ESR2ARCNR1CNR2 | |
| SCHEMBL6905585 | 0.77 | CYP19A1 (0.44) | ESR1CNR1CNR2 | |
| SCHEMBL10411503 | 0.76 | CHEK1 (0.49) | ESR1ESR2ARCNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6689902-B2 | REDUCTIVE ALKYLATION | AJINOMOTO CO., INC. (JP) | 2004-02-10 | — | — | US | claimed |
| US-20030032842-A1 | Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same | AJINOMOTO CO., INC. (JP) | 2003-02-13 | — | — | US | claimed |
| EP-1249442-A1 | NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME | Ajinomoto Co., Inc. (JP) | 2002-10-16 | — | — | EP | claimed |
| US-6689902-B2 | REDUCTIVE ALKYLATION | AJINOMOTO CO., INC. (JP) | 2004-02-10 | — | — | US | disclosed |
| US-20030032842-A1 | Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same | AJINOMOTO CO., INC. (JP) | 2003-02-13 | — | — | US | disclosed |
| EP-1249442-A1 | NOVEL ARYLPROPIONALDEHYDE DERIVATIVES AND PRODUCTION AND USE OF THE SAME | Ajinomoto Co., Inc. (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032842-A1 | Novel arylpropyl aldehyde derivatives, processes for producing the same, and methods of using the same | ALDH7A1, ASPH, DDC | ESR1 4324/4885ESR2 4194/4885AR 3307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.